ESC Congress 2018

25 - 29 August 2018, Munich - Germany

Session Details

Controversies in cardiovascular risk assessment and prevention
Tue 28 Aug 10:05 - 10:55 Risk Factors and Prevention – Cardiovascular Risk Assessment Moderated Posters, Abstract-based Programme Moderated Poster Station - Poster Area
Chairpersons: Angela MAAS (Nijmegen, Netherlands), Axel SCHMERMUND (Frankfurt Am Main, Germany)
Learning Objectives: Moderated Posters are on display from 08:30 to 12:30 on the plasma screen of the topic related Moderated Poster station. During the moderated poster session (10:05-10:55), from a large plasma screen, Presenters will summarise their research within 3 minutes and then address questions from the Chairpersons and Audience.

Access slides, videos, reports online via ESC Congress 365 Other resources

List of Presentations

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
10:05P5082Increased mortality despite successful multifactorial cardiovascular risk reduction in healthy men. 40-year follow-up of the Helsinki businessmen study intervention trialTimo STRANDBERG (Oulu, Finland)
10:05P5083Assessing cardiovascular risk in people with atherosclerotic vascular disease on intensive statin therapyBorislava MIHAYLOVA (Oxford, United Kingdom)
10:05P5084Added predictive value of follow-up blood-pressure measurements after alteration of therapy on cardiovascular risk in patients with hypertensionNicole Elise Maria JASPERS (Utrecht, Netherlands)
10:05P5085Optimizing outreach strategy to identify individuals at risk for diabetes and/or cardiovascular disease: a study of the Sodertalje municipality in SwedenBahira SHAHIM (Stockholm, Sweden)
10:05P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) studyMaciej BANACH (Lodz, Poland)
10:05P5087Sex hormone-binding globulin, aging, and cardiovascular riskElif ARIBAS (Oisterwijk, Netherlands)
10:05P5088Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registryFarid SAAD (Berlin, Germany)